Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • There are nearly 14.5 million people in the U.S. living with a history of cancer.  
  • The standard treatment for prostate cancer used to require radical prostatectomy. Now, less invasive therapies like brachytherapy have been shown to have equal outcomes with fewer side effects.  
  • In the U.S., new cancer drugs have increased life expectancy at birth by 10.7%.  
  • Death rates from breast cancer declined by an average of 2.3% per year between 1990 and 2002 because of earlier detection through screening, better awareness, and improved treatments.  
  • A mammogram can detect breast cancer 1-3 years before a woman can feel a lump. Mammography screening for women 50 and older can reduce breast cancer mortality by 30%.